Alnylam Pharmaceuticals, Inc. news

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients -

- Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- 

– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis –

– Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 –

– Treatment with Patisiran Demonstrated Generally Consistent Benefit Across Prespecified Patient Subgroups on Functional Capacity as Measu

– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months –

– Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- 

– Series Will Culminate in a Virtual R&D Day on December 15, 2022 –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 19, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics

Target knockdown and safety results support continued clinical development

Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022

Detailed results to be presented at an upcoming medical congress

CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022--